Date:	12/13/2022
Your N	Name: Kyle Potts

Manuscript Title: The Role of Bronchoscopy as a Novel Approach in Preoperative Lung Marking for Early-

Stage Lung Cancer

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non- financial interests	None

Kyle Potts has no conflict of interest to disclose.			

Please place an "X" next to the following statement to indicate your agreement:

Date:	12	/13	/2022
-------	----	-----	-------

Your Name: Nakul Ravikumar

Manuscript Title: The Role of Bronchoscopy as a Novel Approach in Preoperative Lung Marking for Early-

**Stage Lung Cancer** 

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non- financial interests	None

Nakul Ravikumar has no conflict of interest to disclose.				

Please place an "X" next to the following statement to indicate your agreement:

Date: 12/13/2022

Your Name: D. Kyle Hogarth

Manuscript Title: The Role of Bronchoscopy as a Novel Approach in Preoperative Lung Marking for Early-

**Stage Lung Cancer** 

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	none	
3	Royalties or licenses	XNone	
4	Consulting fees	Auris	

		Ambu	
		Body Vision	
		Eolo	
		Lanier	
		Noah Medical	
		LX-Medical	
		Preora	
		Wave LifeSciences	
		Magnisity	
		Boston Scientific	
		Johnson and Johnson	
		Oncocyte	
		Veracyte	
		B.I.	
		Level-Ex	
		NovaScan	
		Olympus/Spiration	
		PulmonX	
		Astra-Zeneca	
		Biodesix	
		Genentech	
		Grifols	
		Takeda	
		Ruby Robotics	
		InhibRX	
		Prothea-X	
		TSC	
		Imbio	
		Spesana	
5	Payment or honoraria for	XGrifols, Takeda,	
	lectures, presentations,	Boston Sci, AstraZeneca,	
	speakers bureaus,	Biodesix, BI, Spiration	
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
	_		
_	Dawtisin stirm on a D	In hill Dec	
9	Participation on a Data	_ InhibRx	
	Safety Monitoring Board or		
	Advisory Board		
10			
10			

	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	Gravitas	
		Monogram Orthopedics	
		Noah	
		Body Vision	
		Magnisity	
		Ruby Robotics	
		Ryme	
		Spesana	
		Prothea-X	
		Preora/ASP Health	
		Imbio	
		Eolo	
		Lanier	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
12	Other fire and in Lance	V. N	
13	Other financial or non-	X_None	
	financial interests		

### **Stock Option holder/Stock holder:**

Body Vision, Broncus, Eolo, Eon, Gravitas, Imbio, Lanier, Magnisity, Noah Medical, LX-Medical, Med-Opsys, Monogram Orthopedics, Preora, Preview Med, Prothea-X, Ryme, Ruby Robotics, Spesana, VIDA

### **Consultant within last 3 years:**

Alpha Sights, Ambu, Atheneum, Auris, BioPlusRx, Body Vision, Boston Scientific, Broncus, Coleman, CSL, Deerfield, Eolo, Fluidda, Gala, Gilman Capital, GLG, Grand Rounds, Guidepoint Global, Imbio, InhibRx, J&J, Lanier, Level-Ex, Magnisity, MediFind, Morgan-Stanley, Mosaic, Noah Medical, NovaScan, Olympus (Spiration), Oncocyte, Patients Like Me, Preora, Preview Med, Prothea-X, PulmonX, Qure.ai, Ryme, Ruby Robotics, Serpex, Spesana, Takeda, TSC, Veracyte, Volv, Wave Life Sciences.

# Research Dollars/Contracted Research (past 3 years and present):

Gala, Nuvaira, Olympus (Spiration), PulmonX,

### DSMB member (past0

InhibRx (past)

### Lectures Given (Honoraria received) within the last 3 years:

Astra-Zeneca, Biodesix, B.I., Boston Scientific, Genentech, Grifols, PulmonX, Spiration (Olympus), Takeda

## Please place an "X" next to the following statement to indicate your agreement:

Date:	12/15/2022
Your N	lame: Ajay Wagh

Manuscript Title: The Role of Bronchoscopy as a Novel Approach in Preoperative Lung Marking for Early-

Stage Lung Cancer

Manuscript number	(if known)	:

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial planning of the work		
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None		
		Time frame: past	36 months	
•	Grants or contracts from any entity (if not indicated in item #1 above).	None		
	Royalties or licenses	None		
Ļ	Consulting fees	Noah Medical	Consulting fee to Ajay Wagh	
		Ambu	Consulting fee to Ajay Wagh	
		Medtronic	No fees paid to date.	

	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	Biodesix Speaker  None	Speaking Fee paid to Ajay Wagh
	Support for attending meetings and/or travel	None	
-	Patents planned, issued or pending	None	
	Participation on a Data Safety Monitoring Board or Advisory Board	None	
.0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
.1	Stock or stock options	None	
2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
.3	Other financial or non- financial interests	None	

Ajay Wagh	Ajay Wagh has been a consultant for Noah Medical, Medtronic, and Ambu. He is a Speaker for Biodesix.				

Please place an "X" next to the following statement to indicate your agreement: